Cargando…
Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to dramatic improvements in survival a subset of patients with non-small cell lung cancer (NSCLC); however, they have been shown to cause life-threatening toxicity such as immune checkpoint inhibitor-related pneumonitis (CIP). Our previous stu...
Autores principales: | Chao, Yencheng, Zhou, Jiebai, Hsu, Shujung, Ding, Ning, Li, Jiamin, Zhang, Yong, Xu, Xiaobo, Tang, Xinjun, Wei, Tianchang, Zhu, Zhengfei, Chu, Qian, Neal, Joel W., Wu, Julie Tsu-Yu, Song, Yuanlin, Hu, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902097/ https://www.ncbi.nlm.nih.gov/pubmed/35280322 http://dx.doi.org/10.21037/tlcr-22-72 |
Ejemplares similares
-
Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors
por: Zhou, Jiebai, et al.
Publicado: (2021) -
Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy
por: Zhou, Jiebai, et al.
Publicado: (2023) -
Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020) -
Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020) -
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)